Chemotherapy-induced Nausea and Vomiting
📧 Sign up to get email alerts when something new happens for Chemotherapy-induced Nausea and Vomiting.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2019-09-05FDA Approved: FOSAPREPITANT — Original Application (BluePoint Laboratories)
FDA approved the original application for fosaprepitant, a generic antiemetic, to prevent chemotherapy-induced nausea and vomiting.
-
FDA approval · 2019-09-05FDA Approved: FOSAPREPITANT — Original Application (Baxter Healthcare Corporation)
The FDA approved Baxter's original application for fosaprepitant dimeglumine (fosaprepitant) as an antiemetic to prevent chemotherapy-induce…
-
FDA approval · 2019-09-05FDA Approved: FOSAPREPITANT — Original Application (BE Pharmaceuticals Inc.)
FDA approved the original application for Fosaprepitant filed by BE Pharmaceuticals Inc. (ANDA212309). Fosaprepitant is used to prevent chem…
-
FDA approval · 2019-09-05FDA Approved: FOSAPREPITANT — Original Application (Novadoz Pharmaceuticals LLC)
FDA approves Novadoz Pharmaceuticals' Fosaprepitant via original ANDA, making a generic IV antiemetic available for prevention of chemothera…
-
CLINICAL_TRIALS trial_result · 2019-08-20Clinical Trial Update: "Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC)" [Phase 3]
Phase 3 trial evaluating olanzapine for prevention of chemotherapy-induced nausea and vomiting in children and adolescents receiving highly …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2019-05-24FDA Approved: METOCLOPRAMIDE HYDROCHLORIDE — Supplemental Application (Lupin Pharmaceuticals,Inc.)
The FDA approved Lupin Pharmaceuticals' supplemental application for metoclopramide hydrochloride, authorizing an updated approval for this …
-
CLINICAL_TRIALS trial_result · 2019-05-09Clinical Trial Update: Combination of Netupitant and Palonosetron (Akynzeo®) in the Treatment of Refractory CINV [Phase 2]
A Phase 2 trial evaluating a combination of netupitant and palonosetron (Akynzeo) for refractory chemotherapy-induced nausea and vomiting ha…
-
CLINICAL_TRIALS trial_result · 2019-03-12Clinical Trial Update: Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy [Phase 2]
Phase 2 dose-finding study of APD403 for prevention of nausea and vomiting after chemotherapy has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2019-03-05Clinical Trial Update: NEPA to Prevent Chemotherapy Induced Nausea and Vomiting in Patients With Breast Cancer [Phase 2]
Phase 2 clinical trial update evaluating NEPA to prevent chemotherapy-induced nausea and vomiting in breast cancer patients (completed).
-
FDA approval · 2019-02-26FDA Approved: CINVANTI — Supplemental Application (Heron Therapeutics, Inc.)
The FDA approved a supplemental application for CINVANTI (aprepitant) from Heron Therapeutics, expanding its labeling/indication.
-
FDA approval · 2018-11-06FDA Approved: PALONOSETRON HYDROCHLORIDE — Original Application (Eugia US LLC)
The FDA approved Eugia US LLC's original application for palonosetron hydrochloride (generic) to prevent chemotherapy- and postoperative-ind…
-
FDA approval · 2018-09-19FDA Approved: PALONOSETRON — Original Application (Fresenius Kabi USA, LLC)
FDA approved Fresenius Kabi USA, LLC's original application for Palonosetron, a generic antiemetic, for the prevention of chemotherapy- and …
-
FDA approval · 2018-09-19FDA Approved: PALONOSETRON — Original Application (Fresenius Kabi USA, LLC)
The FDA approved Fresenius Kabi USA, LLC's original application for Palonosetron, a 5-HT3 receptor antagonist used to prevent chemotherapy-i…
-
FDA approval · 2018-09-19FDA Approved: PALONOSETRON HYDROCHLORIDE — Original Application (Mylan Institutional LLC)
FDA approved a generic palonosetron hydrochloride product from Mylan Institutional LLC through an original ANDA, intended to prevent postope…
-
FDA approval · 2018-09-19FDA Approved: PALONOSETRON HYDROCHLORIDE — Original Application (Sagent Pharmaceuticals)
FDA approved Palonosetron hydrochloride as a generic product through an Original Application filed by Sagent Pharmaceuticals.
-
FDA approval · 2018-09-19FDA Approved: PALONOSETRON — Original Application (Apotex Corp.)
FDA approved Apotex Corp.'s original application for a generic palonosetron hydrochloride product to prevent chemotherapy- and surgery-induc…
-
CLINICAL_TRIALS research · 2018-07-26Clinical Trial Update: The Efficacy and Safety of Thalidomide in Preventing CINV Induced by Cisplatin-containing Chemotherapy [NA]
A clinical trial update assessing whether thalidomide can prevent chemotherapy-induced nausea and vomiting caused by cisplatin-containing re…
-
CLINICAL_TRIALS research · 2018-07-05Clinical Trial Update: Trial to Evaluate Efficacy of Olanzapine With Short-acting 5HT3 Inhibitors in Chemotherapy-induced Nausea & Vomiting (CINV) Prophylaxis [Phase 2]
A Phase 2 clinical trial update evaluating whether adding olanzapine to short-acting 5-HT3 inhibitors improves prevention of chemotherapy-in…
-
CLINICAL_TRIALS trial_result · 2018-06-20Clinical Trial Update: An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting [Phase 3]
Phase 3 trial evaluating intravenous palonosetron given as an infusion versus a bolus for prevention of chemotherapy-induced nausea and vomi…
-
CLINICAL_TRIALS trial_result · 2018-06-20Clinical Trial Update: A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting [Phase 3]
Complete Phase 3 safety study evaluating intravenous netupitant (Pro-Netupitant) in combination with palonosetron for prevention of chemothe…
-
FDA approval · 2018-04-23FDA Approved: ONDANSETRON — Supplemental Application (Taro Pharmaceuticals U.S.A., Inc.)
The FDA approved a supplemental application for ondansetron hydrochloride from Taro Pharmaceuticals U.S.A., Inc., for an already approved pr…
-
FDA approval · 2018-04-19FDA Approved: AKYNZEO — Original Application (Helsinn Therapeutics (U.S.), Inc.)
FDA approved the original application for AKYNZEO, a fixed-dose combination of fosnetupitant and palonosetron, to prevent chemotherapy-induc…
-
FDA approval · 2018-04-13FDA Approved: VARUBI — Supplemental Application (TerSera Therapeutics LLC)
FDA approved a supplemental application for VARUBI (rolapitant) submitted by TerSera Therapeutics LLC.
-
FDA approval · 2018-04-12FDA Approved: DRONABINOL — Supplemental Application (Wellhouse Pharma, LLC)
The FDA approved a supplemental application for dronabinol submitted by Wellhouse Pharma, LLC.
-
FDA approval · 2018-04-03FDA Approved: EMEND — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approved a supplemental application for EMEND (fosaprepitant dimeglumine) by Merck Sharp & Dohme LLC.